A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer

A Single-arm, Open-label Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of Hypoxia-Inducible CD73/AXL-Targeting CAR-T Cells (XW-LTH-03) in Patients With Advanced Gastric Cancer

This is a single-arm, open-label clinical study evaluating the safety and preliminary efficacy of a novel hypoxia-inducible, bispecific CD73/AXL-targeting CAR-T cell product, XW-LTH-03, in patients with stage IV gastric cancer (GC). The primary objective is to assess the safety and tolerability of XW-LTH-03 infusions. Secondary objectives include the evaluation of its antitumor efficacy and the characterization of its pharmacokinetic profile by measuring the in vivo expansion and persistence of the CAR-T cells. Exploratory analyses aim to identify potential biomarkers associated with clinical response and toxicity, as well as to investigate the cellular and molecular mechanisms underlying potential treatment resistance.

Study Overview

• Status: Not yet recruiting
• Conditions: Stage IV Gastric Cancer
• Intervention / Treatment: Biological: XW-LTH-03 Infusion

• Study Type: Interventional
• Enrollment (Estimated): 42
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Zhaoming Wang; Phone Number: 021-64041990; Email: wang.zhaoming@zs-hospital.sh.cn

Study Locations

• China
  • Shanghai Municipality
    • Shanghai, Shanghai Municipality, China, 200032
      • Fudan University Zhongshan Hospital
      • Contact: Zhaoming Wang; Phone Number: 021-64041990; Email: wang.zhaoming@zs-hospital.sh.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Aged 18 to 75 years, male or female.
2. Clinically judged as unresectable Stage IV gastric cancer that has progressed on or is intolerant to standard therapy, or patients who voluntarily forego standard therapy.
3. Patients must provide tumor tissue samples, with positive AXL and CD73 confirmed by immunohistochemical (IHC) staining at a central laboratory: AXL positivity rate ≥50% with staining intensity ≥++, and CD73 positivity rate ≥30% with staining intensity ≥+.
4. ECOG Performance Status score of ≤ 1.
5. Life expectancy of ≥ 3 months.
6. At least one measurable lesion (≥ 1 cm).
7. More than 4 weeks since the last failed treatment, and any toxicities from previous treatments must have recovered to Grade ≤ 1.
8. Adequate organ function and bone marrow reserve, as defined by the following laboratory values within a specified period before enrollment:

1. Hemoglobin (Hb) ≥ 90 g/L. 2. Absolute Neutrophil Count (ANC) ≥ 1.0 × 10^9/L. 3. Absolute Lymphocyte Count ≥ 0.5 × 10^9/L. 4. Platelet count ≥ 100 × 10^9/L. 5. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × upper limit of normal (ULN).

6. Serum amylase and lipase ≤ 1.0 × ULN. 7. Total bilirubin ≤ 1.5 × ULN. 8. Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min (calculated by the Cockcroft-Gault formula).

9. Prothrombin Time (PT) or International Normalized Ratio (INR), and Partial Thromboplastin Time (PTT) < 1.5 × ULN. (Patients receiving warfarin or heparin anticoagulation therapy may be enrolled if no underlying abnormality in these parameters is suspected, but require close monitoring with at least weekly testing until INR is stable).

9. Adequate cardiac and pulmonary function. 10. Women of childbearing potential must have a negative pregnancy test within 7 days before treatment initiation. All subjects must agree to use effective contraception during the treatment period and for 1 year thereafter.

11. Voluntary signing of a written informed consent form, good compliance, and willingness to cooperate with follow-up.

Exclusion Criteria:

1. Active, known, or highly suspected autoimmune disease.
2. Patients with brain metastases who have active central nervous system symptoms. (Note: Patients with brain metastases who completed radiotherapy at least 3 months prior to enrollment and remain asymptomatic from CNS disease may be eligible).
3. Active, uncontrolled systemic infection.
4. Receiving high-dose corticosteroids (>10 mg/day of methylprednisolone or equivalent doses of other corticosteroids) or other immunosuppressive therapy within 14 days prior to enrollment.
5. History of severe allergy to other monoclonal antibodies.
6. Intolerance or allergy to the investigational drug.
7. History of interstitial lung disease.

8. Evidence of organ failure:

   • Cardiac: Class III or IV heart failure (per NYHA or other applicable criteria).
   • Hepatic: Class C liver function as per Child-Pugh score.
   • Renal: Renal failure or uremia stage.
   • Pulmonary: Symptoms of severe respiratory failure.
   • Neurological: Impaired consciousness.
9. Active Hepatitis B (HBsAg positive with detectable HBV DNA), active Hepatitis C (HCV RNA positive), or HIV antibody positive.
10. History of organ transplantation.
11. Active gastrointestinal bleeding, or history of gastrointestinal bleeding within the past month.
12. History of drug abuse, or psychological/psychiatric disorders that may compromise compliance with the study.
13. Any unstable condition or situation that may jeopardize the patient's safety or compliance in the study.
14. Thyroid dysfunction.
15. Prior treatment with any form of adoptive T-cell therapy.
16. Currently receiving anticoagulant or antiplatelet therapy.
17. Major surgery or significant trauma within 4 weeks prior to enrollment.
18. History of other malignant tumors within the past 3 years.
19. Judged by the investigator as unsuitable for cell therapy.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: XW-LTH-03 Infusion	Biological: XW-LTH-03 Infusion; CD73/AXL-Targeting Hypoxia-Inducible CAR-T

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)	3 months
Incidence of Dose-Limiting Toxicities (DLTs)	3 months
Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D)	3 months

Collaborators and Investigators

• Sponsor: Shanghai Zhongshan Hospital
• Collaborators: SHANGHAI SINOBAY BIOTECHNOLOGY CO., LTD

Study record dates

Study Major Dates

• Study Start (Estimated): January 1, 2026
• Primary Completion (Estimated): June 30, 2027
• Study Completion (Estimated): June 30, 2027

Study Registration Dates

• First Submitted: September 23, 2025
• First Submitted That Met QC Criteria: December 30, 2025
• First Posted (Estimated): January 12, 2026

Study Record Updates

• Last Update Posted (Estimated): January 12, 2026
• Last Update Submitted That Met QC Criteria: December 30, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases; Stomach Neoplasms
• Other Study ID Numbers: ZSGC-CD73AXL-CART

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No